Cardiogeni (AQSE:CGNI) Beta: N/A (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiogeni Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-11), Cardiogeni's Beta is Not available.

Cardiogeni  (AQSE:CGNI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Cardiogeni Beta Related Terms

Cardiogeni Beta Historical Data

* Premium members only.

The historical data trend for Cardiogeni's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiogeni Beta Chart

Cardiogeni Annual Data
Trend
Beta

Cardiogeni Semi-Annual Data
Beta

Cardiogeni Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Cardiogeni Business Description

Comparable Companies
Address Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford upon Avon, GBR, CV37 7GZ
Cardiogeni PLC is engaged in the development and commercialisation of a portfolio of novel cellular medicines for heart failure. The Company focuses on the development and commercialisation of novel cellular medicines targeting early- and mid-stage heart failure. Its strategic priority is to complete a pivotal Phase 2b/3 study and obtain first market approval for its product, CLXR-001, in a suitable jurisdiction, and then establish strategic funding and collaboration agreements to develop and commercialise the product in the US, EU, Japan, and other jurisdictions.